ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Chlamydia mRNA Vaccine

Its studies are mostly in Chlamydia Infections, led by Sanofi.

Furthest: phase 1, since Mar 17, 20251 company-led study, 1 open or runningNext primary completion: Nov 3, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 1since Mar 17, 2025Mar 17, 2025Nov 3, 2027phase 1 · NCT06891417

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 17, 2025First study: phase 1 study in Chlamydia InfectionsFirst studyNCT06891417 · 80 planned · Australia

Ahead

  1. Nov 3, 2027Primary completion: phase 1 study in Chlamydia InfectionsNCT06891417

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Chlamydia mRNA Vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06891417Chlamydia Infections · Australia1RecruitingNov 3, 202780

How it is read

Names in the registry

  • “Chlamydia mRNA Vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.